ECSP17058071A - Derivados de tetrahidropiranil benzamida - Google Patents

Derivados de tetrahidropiranil benzamida

Info

Publication number
ECSP17058071A
ECSP17058071A ECIEPI201758071A ECPI201758071A ECSP17058071A EC SP17058071 A ECSP17058071 A EC SP17058071A EC IEPI201758071 A ECIEPI201758071 A EC IEPI201758071A EC PI201758071 A ECPI201758071 A EC PI201758071A EC SP17058071 A ECSP17058071 A EC SP17058071A
Authority
EC
Ecuador
Prior art keywords
tetrahydropyranil
benzamide derivatives
compounds
benzamide
derivatives
Prior art date
Application number
ECIEPI201758071A
Other languages
English (en)
Inventor
Haizhen Zhang
Jingye Zhou
zhi long Hu
Tianwei Ma
Lian Zhu Liu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP17058071A publication Critical patent/ECSP17058071A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula siguiente: en donde R, R1-R3 son como se describen en la presente; métodos para tratar pacientes por diabetes usando los compuestos, y procesos para preparar los compuestos.
ECIEPI201758071A 2015-03-03 2017-09-01 Derivados de tetrahidropiranil benzamida ECSP17058071A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/073563 WO2016138631A1 (en) 2015-03-03 2015-03-03 Imidazo benzamide compounds

Publications (1)

Publication Number Publication Date
ECSP17058071A true ECSP17058071A (es) 2017-10-31

Family

ID=56849060

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201758071A ECSP17058071A (es) 2015-03-03 2017-09-01 Derivados de tetrahidropiranil benzamida

Country Status (24)

Country Link
US (1) US10196385B2 (es)
EP (1) EP3265460A4 (es)
JP (1) JP2018507232A (es)
KR (1) KR20170106483A (es)
CN (1) CN107406436B (es)
AU (1) AU2016228055B2 (es)
BR (1) BR112017015448A2 (es)
CA (1) CA2975413A1 (es)
CL (1) CL2017002148A1 (es)
CO (1) CO2017008721A2 (es)
CR (1) CR20170354A (es)
DO (1) DOP2017000196A (es)
EA (1) EA201791745A1 (es)
EC (1) ECSP17058071A (es)
IL (1) IL253405A0 (es)
MA (1) MA41641A (es)
MX (1) MX2017011087A (es)
PE (1) PE20171650A1 (es)
PH (1) PH12017501560A1 (es)
SG (1) SG11201706718RA (es)
SV (1) SV2017005520A (es)
TN (1) TN2017000372A1 (es)
WO (2) WO2016138631A1 (es)
ZA (1) ZA201704948B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014337A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide
BR112020018286A2 (pt) 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
CN122055357A (zh) * 2024-09-13 2026-05-15 成都麻沸散医药科技有限公司 一种杂环化合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045484A1 (en) 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
EP2404896A1 (en) * 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Cyclohexane derivative having npy y5 receptor antagonism
EP2523558A4 (en) * 2010-01-15 2013-06-19 Merck Sharp & Dohme OXADIAZOL BETA CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS
WO2012123449A1 (en) 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators
WO2015120610A1 (en) 2014-02-14 2015-08-20 Eli Lilly And Company Gpr142 agonist compound

Also Published As

Publication number Publication date
US20180194755A1 (en) 2018-07-12
SV2017005520A (es) 2018-08-27
EP3265460A1 (en) 2018-01-10
MX2017011087A (es) 2017-11-10
US10196385B2 (en) 2019-02-05
DOP2017000196A (es) 2017-09-15
CR20170354A (es) 2017-09-05
WO2016138631A1 (en) 2016-09-09
KR20170106483A (ko) 2017-09-20
IL253405A0 (en) 2017-09-28
ZA201704948B (en) 2019-02-27
AU2016228055A1 (en) 2017-08-17
EP3265460A4 (en) 2018-08-08
CO2017008721A2 (es) 2018-01-05
MA41641A (fr) 2018-01-09
CN107406436B (zh) 2021-02-26
TN2017000372A1 (en) 2019-01-16
CA2975413A1 (en) 2016-09-09
EA201791745A1 (ru) 2018-01-31
AU2016228055B2 (en) 2018-06-07
SG11201706718RA (en) 2017-09-28
CL2017002148A1 (es) 2018-04-13
JP2018507232A (ja) 2018-03-15
CN107406436A (zh) 2017-11-28
BR112017015448A2 (pt) 2018-01-30
PH12017501560A1 (en) 2018-02-05
PE20171650A1 (es) 2017-11-13
WO2016138821A1 (en) 2016-09-09

Similar Documents

Publication Publication Date Title
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
BR112016023558A2 (pt) compostos úteis como imunomoduladores
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
BR112017017396A2 (pt) derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CO2017000065A2 (es) Indoles funcionalizados y sustituidos como agentes anti-cáncer
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
DOP2016000211A (es) Pirazinas moduladoras de gpr6
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
NI201200195A (es) Procedimiento de preparación de la sal de l - arginina de perindoprilo
CY1124164T1 (el) Καινοτομος παρασκευη και κρυσταλλωση της ιοσιμενολης
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
BR112018070345A2 (pt) processo para a preparação de derivados de 4-aminoindano e amidas de aminoindano relacionadas
MX382702B (es) Nuevos compuestos de sulfonilaminobenzamida como antihelminticos.
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
BR112016011899A2 (pt) Processo para preparação de 5-fluoro-1h-pirazóis
DOP2017000196A (es) Derivados de tetrahidropiranil benzamida
MX2019002607A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.